22.418 articles found

Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

Pahwa R, Factor SA, Lyons KE, Ondo WG, Gronseth G, Bronte-Stewart H, Hallett M, Miyasaki J, Stevens J, Weiner WJ, Quality Standards Subcommittee of the American Academy of Neurology.

Neurology · 2006-04-01

DOI: 10.1212/01.wnl.0000215250.82576.87PMID: 16606909

Motor system inhibition in dopa-responsive dystonia and its modulation by treatment.

Huang YZ, Trender-Gerhard I, Edwards MJ, Mir P, Rothwell JC, Bhatia KP.

Neurology · 2006-04-01

DOI: 10.1212/01.wnl.0000214304.03105.f4PMID: 16606922

MPTP treatment of common marmosets impairs proteasomal enzyme activity and decreases expression of structural and regulatory elements of the 26S proteasome.

Zeng BY, Iravani MM, Lin ST, Irifune M, Kuoppamäki M, Al-Barghouthy G, Smith L, Jackson MJ, Rose S, Medhurst AD, Jenner P.

Eur J Neurosci · 2006-04-01

DOI: 10.1111/j.1460-9568.2006.04718.xPMID: 16623833

Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms.

Hedenmalm K, Güzey C, Dahl ML, Yue QY, Spigset O.

J Clin Psychopharmacol · 2006-04-01

DOI: 10.1097/01.jcp.0000203200.96205.34PMID: 16633151

Cabergoline scavenges peroxynitrite enhanced by L-DOPA therapy in patients with Parkinson's disease.

Isobe C, Abe T, Kikuchi T, Murata T, Sato C, Terayama Y.

Eur J Neurol · 2006-04-01

DOI: 10.1111/j.1468-1331.2006.01207.xPMID: 16643311

Protein-misfolding diseases and chaperone-based therapeutic approaches.

Chaudhuri TK, Paul S.

FEBS J · 2006-04-01

DOI: 10.1111/j.1742-4658.2006.05181.xPMID: 16689923

[Progress and clashes in stem cell therapy research].

Mummery CL, van Laake LW.

Ned Tijdschr Geneeskd · 2006-04-01

PMID: 17225733

Neurophysiologic intervention in deep brain stimulation treatment for movement disorders: a practical framework.

Liu X, Bain PG, Aziz TZ.

Neuromodulation · 2006-04-01

DOI: 10.1111/j.1525-1403.2006.00051.xPMID: 22151635

Use of aminoguanidine or aminoguanidine analogs for the treatment of diseases of the nervous system

KADDURAH-DAOUK RIMA.

· 2006-03-31

TREATMENT OF PARKINSON'S DISEASE, OBSTRUCTIVE SLEEP APNEA, DEMENTIA WITH LEWY BODIES, VASCULAR DEMENTIA WITH NON-IMIDAZOLE ALKYLAMINES HISTAMINE H3-RECEPTOR LIGANDS

SCHWARTZ Jean-Charles, LECOMTE Jeanne-Marie.

· 2006-03-30

TREATMENT OF PARKINSON'S DISEASE, OBSTRUCTIVE SLEEP APNEA, DEMENTIA WITH LEWY BODIES, VASCULAR DEMENTIA WITH NON-IMIDAZOLE ALKYLAMINES HISTAMINE H3-RECEPTOR LIGANDS

SCHWARTZ JEAN-CHARLES, LECOMTE JEANNE-MARIE.

· 2006-03-30

Treatment of parkinson's disease, obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3-receptor ligands

SCHWARTZ JEAN-CHARLES, LECOMTE JEANNE-MARIE.

· 2006-03-30